Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
Fulgent Genetics (NASDAQ: FLGT) announced that CFO Paul Kim and CCO Brandon Perthuis will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 11, 2020, at 3:30 p.m. ET. A live webcast of the presentation will be accessible on the company’s Investor Relations website.
The company offers comprehensive testing solutions, including its proprietary technology platform for genetic testing and COVID-19 detection, supported by Emergency Use Authorization from the FDA for its RT-PCR tests and at-home testing services.
- None.
- None.
TEMPLE CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on Wednesday, November 11, 2020. These representatives of the company will host a presentation beginning at 3:30 p.m. ET.
A live webcast of the presentation will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com.
About Fulgent Genetics
Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (“COVID-19”), including NGS and reverse transcription polymerase chain reaction (“RT-PCR”) - based tests. The Company has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated laboratory services.
Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633; nicole@blueshirtgroup.com
FAQ
When is Fulgent Genetics participating in the Credit Suisse conference?
Who from Fulgent Genetics will present at the Credit Suisse conference?
Where can I watch the Fulgent Genetics presentation live?
What is the significance of Fulgent Genetics' technology platform?
What COVID-19 testing solutions has Fulgent Genetics launched?
Has Fulgent Genetics received FDA approval for its tests?
